|2022-11-16||Morgan Stanley’s 21st Annual Asia Pacific Summit||Singapore|
|2022-11-22||CICC Investment Forum||Virtual|
|2022-12-15||Gelonghui Global Investment Summit||Shenzhen|
CMS has been deeply engaged in the Chinese pharmaceutical market for 30 years, and has always maintained its patient-centered philosophy. We are dedicated to providing competitive products and services that enable the more effective diagnosis and treatment, whilst enhancing clinical practice to the ultimate benefit of the patient.
We have built four major business segments: cardio-cerebrovascular and gastroenterology, dermatology and medical aesthetics, ophthalmology, and consumer healthcare. These divisions are run as independent business units, driving growth and cultivating an entrepreneurial spirit, whilst allowing them to benefit from the scale advantages and operational efficiencies inherent with being part of a larger group and empowering the divisions to gain leading positions in specialty markets.
We have a mature commercialization platform that is compliant with international standards, efficient, fosters resource-sharing amongst teams, includes a professional and highly qualified promotion team with strong execution capability, and a wide range of expert networks in specialty fields. This creates deep insights into clinical needs and deep experience in market access, academic promotion, government affairs and brand building, allowing CMS to build a long track-record of developing market-leading positions for a number of products.
Based on our commercialization platform and deep market understanding, we have deployed differentiated innovative products globally and efficiently promoted clinical development and commercialization of the products in China, so as to benefit patients.